Therefore, while CTHRC1 and the BRAF(V600E) mutation serve as diagnostic and prognostic biomarkers in melanoma, they cannot simply be considered oncogenic biomarkers and exhibit tissue specificity. The gene discussed is BRAF; the disease is melanoma.